- Conditions
- Age Related Macular Degeneration
- Interventions
- Longvida curcumin, placebo
- Drug · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–86
of 86
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Age-Related Macular Degeneration
- Interventions
- ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin
- Drug
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Dry Eye Syndromes, Age-Related Macular Degeneration, Omega 3 Index
- Interventions
- OmegaBoost, Nature Made (soft gel), Nature Made (gummy)
- Dietary Supplement
- Lead sponsor
- Western University of Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Pomona, California
- Conditions
- Dry Macular Degeneration
- Interventions
- SS-OCT imaging
- Device
- Lead sponsor
- Boston Image Reading Center
- Industry
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- brolucizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Fort Lauderdale, Florida • Indianapolis, Indiana + 2 more
- Conditions
- Geographic Atrophy
- Interventions
- Vonaprument, Sham Administration
- Drug · Other
- Lead sponsor
- Annexon, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 659 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 71
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Fullerton, California + 64 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- ACU-4429, Matching placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- Duke University
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration, Macular Degeneration
- Interventions
- RN6G, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 24
- States / cities
- Campbell, California • Los Gatos, California • San Jose, California + 7 more
- Conditions
- Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
- Interventions
- High Dose NT-501 implant, Low Dose NT-501 implant, Sham
- Combination Product · Other
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
- Conditions
- Geographic Atrophy
- Interventions
- ACU-4429, Placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Age Related Macular Degeneration, Macular Degeneration, AMD
- Interventions
- HuCNS-SC cells
- Drug
- Lead sponsor
- StemCells, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • New York, New York + 2 more
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- LFG316, Sham, LFG316 Lower dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
- Interventions
- GT005, GT005 / Device: Orbit™ Subretinal Delivery System
- Biological · Device
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Indianapolis, Indiana • West Des Moines, Iowa • Boston, Massachusetts + 4 more